Alcohol use curbed by anti-nausea medication, study finds

January 25, 2011 By Shari Roan

Alcoholics who were given a medication approved for quelling nausea were able to cut back on their alcohol intake, researchers reported this week. The medication, ondansetron (Zofran), could become a readily available therapy for helping some alcoholics become abstinent.

The study, published Wednesday in the , is based on research on a gene known as 5-HTT that is important to the serotonin system of the brain. Certain variants of this gene can increase the risk of , such as depression, anxiety, obsessive-compulsive disorder and addiction.

Ondansetron is used to prevent nausea and vomiting caused by . But it's in a class of medications that work by blocking serotonin. The study tested the idea that a drug to block this neurotransmitter in genetically susceptible people might reduce the severity of their drinking.

Researchers analyzed the of 283 alcoholics who were still drinking. They found that those with the 5-HTT LL genotype who received ondansetron took fewer drinks per day and had more days of abstinence over the 11-week study compared with people with the LL genotype who did not receive the drug. All the study participants received cognitive-behavioral therapy aimed at helping them become abstinent.

Among the patients who received ondansetron, those with the LL genotype or another variant called LL/TT cut back on their drinking enough to move out of the "high-risk" category of drinkers. But the drug did not seem to help patients who had other forms of the 5-HTT genotype.

The study was led by Bankole A. Johnson, chairman of the department of psychiatry and neurobehavioral sciences at the University of Virginia, and an expert in medications used to treat addiction. His paper on the use of topiramate - an anti-seizure medication - to treat alcoholism was published in the Journal of the American Medical Association in 2007.

In an e-mail, Johnson said that ondansetron had a stronger effect on promoting abstinence than topiramate in the LL genotype group. "Genotyping is becoming more common place and inexpensive," he said, opening the door to tailoring addiction treatment based on an individual's genes.

shares

Related Stories

Recommended for you

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

Fentanyl drives rise in opioid-linked deaths in U.S.

August 31, 2017
(HealthDay)—Fentanyl, a synthetic narcotic, is a key player in America's continuing epidemic of opioid-related overdose deaths, two new studies report.

Eating triggers endorphin release in the brain

August 28, 2017
Finnish researchers have revealed how eating stimulates brain's endogenous opioid system to signal pleasure and satiety.

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.